Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of two adagrasib dosing regimens in previously treated KRAS G12C-mutated non-small cell lung cancer
2023-503523-25-00Phase 2Authorised
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate. Planned start Feb 2024; status: authorised.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503523-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503523-25-00.